Immunovant Inc (NASDAQ: IMVT)’s stock price has decreased by -0.42 compared to its previous closing price of 28.52. However, the company has seen a -1.15% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-11-08 that IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
Moreover, the 36-month beta value for IMVT is 0.63. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMVT is 62.14M and currently, short sellers hold a 20.95% of that float. On December 06, 2024, IMVT’s average trading volume was 895.59K shares.
IMVT’s Market Performance
IMVT’s stock has seen a -1.15% decrease for the week, with a -6.33% drop in the past month and a -16.54% fall in the past quarter. The volatility ratio for the week is 2.96%, and the volatility levels for the past 30 days are at 4.44% for Immunovant Inc The simple moving average for the past 20 days is 1.47% for IMVT’s stock, with a -3.86% simple moving average for the past 200 days.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Raymond James repeating the rating for IMVT by listing it as a “Outperform.” The predicted price for IMVT in the upcoming period, according to Raymond James is $36 based on the research report published on October 10, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see IMVT reach a price target of $53, previously predicting the price at $47. The rating they have provided for IMVT stocks is “Outperform” according to the report published on October 09th, 2024.
Oppenheimer gave a rating of “Outperform” to IMVT, setting the target price at $50 in the report published on March 28th of the current year.
IMVT Trading at -1.88% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.69% of loss for the given period.
Volatility was left at 4.44%, however, over the last 30 days, the volatility rate increased by 2.96%, as shares sank -9.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.07% lower at present.
During the last 5 trading sessions, IMVT fell by -1.15%, which changed the moving average for the period of 200-days by -22.19% in comparison to the 20-day moving average, which settled at $27.99. In addition, Immunovant Inc saw -32.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from Pande Atul, who sale 7,750 shares at the price of $28.54 back on Dec 02 ’24. After this action, Pande Atul now owns 86,663 shares of Immunovant Inc, valued at $221,185 using the latest closing price.
Hughes Douglas J., the Director of Immunovant Inc, sale 5,425 shares at $28.54 during a trade that took place back on Dec 02 ’24, which means that Hughes Douglas J. is holding 119,585 shares at $154,830 based on the most recent closing price.
Stock Fundamentals for IMVT
Current profitability levels for the company are sitting at:
- -228.29 for the present operating margin
- 0.87 for the gross margin
The net margin for Immunovant Inc stands at -215.34. The total capital return value is set at -0.76. Equity return is now at value -92.17, with -79.97 for asset returns.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 1.34. When we switch over and look at the enterprise to sales, we see a ratio of 2463.87. The receivables turnover for the company is 0.8for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.61.
Conclusion
To wrap up, the performance of Immunovant Inc (IMVT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
